| Quarterly Financials | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 141 | 138 | 137 | 93 | 120 | 110 | 105 | 131 | 95 | 196 | 164 | 180 | 134 | 171 | 169 | 251 | 185 | 207 | 228 | 231 | 252 | 230 | 226 | 241 | 275 | 204 | 213 | 376 | 306 |
| Expenses | 148 | 133 | 129 | 108 | 100 | 91 | 108 | 123 | 95 | 116 | 151 | 154 | 119 | 147 | 146 | 177 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 210 | 269 | 195 | 213 | 338 | 290 |
| EBITDA | -7 | 6 | 7 | -15 | 21 | 19 | -3 | 8 | 0 | 79 | 13 | 26 | 15 | 24 | 23 | 74 | 24 | 32 | 43 | 42 | 40 | 38 | 35 | 32 | 6 | 9 | 0 | 38 | 16 |
| Operating Profit % | -9 % | -1 % | 0 % | -23 % | 16 % | 17 % | -5 % | -3 % | -3 % | 9 % | 7 % | 13 % | 10 % | 11 % | 9 % | 16 % | 12 % | 12 % | 16 % | 13 % | 13 % | 14 % | 12 % | 12 % | -2 % | -1 % | -3 % | 8 % | 5 % |
| Depreciation | 31 | 32 | 32 | 23 | 30 | 30 | 29 | 20 | 20 | 20 | 20 | 27 | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 11 | 9 | 9 | 11 | 11 |
| Interest | 0 | 0 | 3 | 1 | 14 | 13 | 13 | 12 | 11 | 10 | 7 | 5 | 8 | 9 | 8 | 8 | 6 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 2 | 4 | 3 | 2 | 2 |
| Profit Before Tax | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -6 | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 23 | 19 | -7 | -3 | -12 | 25 | 3 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | -1 | 0 | 1 | 0 | 1 | -3 | -1 | -1 | 2 | -3 | -1 | 2 | 1 | -1 | -1 |
| Net Profit | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -7 | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | -6 | -6 | -13 | 26 | 3 |
| EPS in ₹ | -4.32 | -2.93 | -3.11 | -9.52 | -5.55 | -5.98 | -10.96 | -6.06 | -7.57 | 12.10 | -3.40 | -1.61 | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 4.30 | 6.18 | 6.81 | 5.79 | 5.37 | 4.10 | 4.40 | -0.95 | -1.13 | -2.49 | 4.31 | 0.54 |
Orchid Pharma
Orchid Pharma
965.80
+18.70
(1.97%)
Market Cap
4,898.45 Cr
PE Ratio
528.77
Volume
26,453.00
Day High - Low
968.50 - 937.35
52W High-Low
1,133.00 - 480.00
There are new updates from the company22 hrs ago
View
Key Fundamentals
Market Cap
4,898.45 Cr
EPS
4.05
PE Ratio
528.77
PB Ratio
4.37
Book Value
216.57
EBITDA
34.02
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
7.56
Debt to Equity
0.13
Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
Orchid Pharma Limited has submitted its Business Responsibility and Sustainability Report for FY26 to stock exchanges. The standalone report covers operations ending March 31, 2026, with pharma manufacturing accounting for 97% of turnover.
Orchid Pharma board approves Arjun Dhanuka as Whole-Time Director for a five-year term. The firm also appoints M/s. J Karthikeyan & Associates as cost auditor and schedules its 33rd AGM for September 29, 2026.
Orchid Pharma has scheduled its Q1FY27 earnings call for August 21, 2026, at 3:00 pm IST. The management team will discuss financial results for the quarter ended June 30, 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,885.90 | #1 4,52,490.58 | 37.62 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 42.08 | |
9,575.00 | 2,54,186.17 | 84.45 | 11,067.00 | 13.95 | 2,568 | 65.50 | 73.44 | |
4,960.00 | 1,88,662.46 | 86.68 | 13,886.20 | 20.34 | 2,138 | 3.28 | 51.61 | |
1,145.50 | 1,15,264.10 | 25.09 | 27,657.90 | 17.64 | 5,026 | -34.90 | 50.98 | |
1,384.00 | 1,11,805.79 | 33.60 | 29,044.60 | 2.24 | 3,870 | -39.18 | 37.48 | |
1,946.90 | 1,05,104.68 | 92.58 | 6,867.80 | 22.01 | 890 | #1 123.93 | 66.90 | |
1,692.00 | 97,353.94 | 25.71 | 34,145.20 | 5.56 | 3,503 | 25.21 | 60.75 | |
2,104.70 | 96,233.73 | #1 17.34 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 25.42 | |
1,151.00 | 96,070.41 | 30.02 | 35,058.60 | 3.90 | 4,158 | -69.10 | 40.13 | |
2,309.00 | 95,360.77 | 46.39 | 14,636.40 | 14.85 | 1,938 | 29.13 | 36.72 |
Growth Rate
Revenue Growth
-14.54 %
Net Income Growth
-78.06 %
Cash Flow Change
-84.74 %
ROE
-7.01 %
ROCE
-6.21 %
EBITDA Margin (Avg.)
-73.62 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,911 |
| Fixed Assets | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 633 | 1,032 |
| Current Assets | 1,278 | 1,251 | 675 | 679 | 768 | 569 | 550 | 398 | 501 | 791 | 807 | 684 |
| Capital Work in Progress | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 47 | 31 | 81 | 341 |
| Investments | 0 | 0 | 1 | 1 | 1 | 0 | 15 | 46 | 44 | 46 | 50 | 256 |
| Other Assets | 1,985 | 1,945 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 | 0 |
| Total Equity & Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,911 |
| Current Liabilities | 1,123 | 1,338 | 1,510 | 2,013 | 2,346 | 175 | 142 | 241 | 372 | 260 | 286 | 279 |
| Non Current Liabilities | 2,609 | 2,475 | 2,212 | 1,905 | 1,436 | 519 | 442 | 222 | 165 | 124 | 135 | 344 |
| Total Equity | 329 | 49 | -467 | -792 | -704 | 766 | 653 | 647 | 689 | 1,170 | 1,267 | 1,288 |
| Reserve & Surplus | 244 | -40 | -556 | -881 | -793 | 725 | 544 | 538 | 579 | 1,050 | 1,148 | 1,237 |
| Share Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 18 |
| Investing Activities | 1,334 | -2 | -176 | -28 | 46 | 167 | 67 | 113 | -31 | -312 | -27 |
| Operating Activities | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 93 | 18 | 126 | 19 |
| Financing Activities | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 25 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 98.07 % | 90.00 % | 90.00 % | 90.00 % | 90.00 % | 89.96 % | 89.96 % | 89.96 % | 89.96 % | 72.40 % | 72.40 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.14 % | 1.96 % | 1.42 % | 1.94 % | 2.53 % | 2.69 % | 1.40 % | 1.56 % | 1.17 % | 0.87 % | 0.81 % |
| DIIs | 1.00 % | 3.44 % | 3.35 % | 3.35 % | 2.97 % | 2.97 % | 2.98 % | 3.94 % | 2.62 % | 13.49 % | 9.88 % | 14.50 % | 17.73 % | 18.93 % | 18.29 % | 18.99 % | 20.10 % | 19.43 % | 19.04 % | 19.39 % | 20.25 % | 20.75 % |
| Government | 0.00 % | 0.00 % | 0.04 % | 0.04 % | 0.04 % | 0.04 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.58 % | 2.34 % | 2.72 % | 2.83 % | 3.34 % | 3.69 % | 3.61 % | 3.44 % | 3.38 % | 3.10 % | 3.85 % | 7.79 % | 7.44 % | 7.16 % | 7.59 % | 6.42 % | 5.11 % | 6.91 % | 7.03 % | 6.76 % | 6.58 % | 6.21 % |
| Others | 0.35 % | 4.22 % | 3.89 % | 3.79 % | 3.65 % | 3.34 % | 3.44 % | 2.66 % | 4.03 % | 11.02 % | 13.87 % | 3.74 % | 3.03 % | 2.65 % | 2.35 % | 2.22 % | 2.27 % | 2.43 % | 2.54 % | 2.84 % | 2.47 % | 2.40 % |
| No of Share Holders | 30,343 | 33,379 | 34,798 | 33,535 | 33,698 | 33,679 | 32,717 | 30,894 | 29,523 | 29,039 | 29,197 | 36,931 | 36,720 | 34,695 | 36,363 | 34,158 | 34,303 | 39,827 | 38,155 | 35,709 | 35,118 | 33,433 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Sept 2026 |  Annual General Meeting | NA | 29 Sept 2026 | 938.50 | 946.50 |
| 21 Aug 2024 | Annual General Meeting | NA | 21 Aug 2024 | 1,147.85 | 1,398.00 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 1,394.75 | 1,499.45 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,457.50 | 1,245.55 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 759.20 | 754.40 |
| 26 Jun 2025 |  Extraordinary General Meeting | NA | 26 Jun 2025 | 669.00 | 701.95 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 800.85 | 780.15 |
| 20 Sept 2025 | Annual General Meeting | NA | 20 Sept 2025 | 780.15 | 788.55 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 789.30 | 846.25 |
| 11 Feb 2026 | Quarterly Result Announcement | NA | 11 Feb 2026 | 688.40 | 687.80 |
| 25 May 2026 | Quarterly Result Announcement | NA | 25 May 2026 | 713.10 | 708.00 |
| 23 Jul 2026 |  Merger - Demerger | 5:161 | 23 Jul 2026 | 1,001.45 | 1,001.45 |
| 14 Aug 2026 | Quarterly Result Announcement | NA | 14 Aug 2026 | 1,076.60 | 1,033.50 |
Announcements
Reg. 34 (1) Annual Report.
1 hr ago
1 hr agoBusiness Responsibility and Sustainability Reporting (BRSR)6 hrs ago
6 hrs agoNotice Of 33Rd Annual General Meeting Of Orchid Pharma Limited (The Company) For The F.Y. 2025-2622 hrs ago
22 hrs agoAnnouncement under Regulation 30 (LODR)-Change in Management5 days ago
5 days agoBoard Meeting Outcome for Outcome Of Board Meeting5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call TranscriptAug 24, 2026
Aug 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 21, 2026
Aug 21, 2026Announcement under Regulation 30 (LODR)-Investor PresentationAug 20, 2026
Aug 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 17, 2026
Aug 17, 2026Statement Of Deviation Or Variation For The Quarter Ended June 30 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional PlacementAug 14, 2026
Aug 14, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 14, 2026
Aug 14, 2026Outcome Of Board Meeting Held For Considering And Approving Revised Audited Financial Results For The Year Ended March 31 2026 Pursuant To Scheme Of Merger.Aug 14, 2026
Aug 14, 2026Financial Results For Quarter-1 Of F.Y. 2026-27 Ended June 30 2026.Aug 14, 2026
Aug 14, 2026Board Meeting Outcome for Outcome Of Board MeetingAug 14, 2026
Aug 14, 2026Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 14 2026.Aug 11, 2026
Aug 11, 2026Announcement under Regulation 30 (LODR)-AllotmentAug 01, 2026
Aug 01, 2026Board Meeting Outcome for Outcome Of Board Meeting Held On August 01 2026Aug 01, 2026
Aug 01, 2026Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 01 2026Jul 28, 2026
Jul 28, 2026Intimation Regarding Investor RoadshowJul 25, 2026
Jul 25, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2026
Jul 11, 2026Corporate Action For Fixation Of Record DateJul 10, 2026
Jul 10, 2026Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJul 10, 2026
Jul 10, 2026Board Meeting Outcome for Intimation Under Regulations 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended ("SEBI Listing Regulations").Jul 10, 2026
Jul 10, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company/Company) And Their Respective Shareholders
And Creditors (The Scheme) Under Regulation 30 Of SEBI (ListingJul 10, 2026
Jul 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 07, 2026
Jul 07, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited And Orchid Pharma LimitedJun 12, 2026
Jun 12, 2026Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJun 11, 2026
Jun 11, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (Listing ObligatiJun 05, 2026
Jun 05, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 01, 2026
Jun 01, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2026
May 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2026
May 26, 2026Appointment Of Internal Auditor Of The CompanyMay 25, 2026
May 25, 2026Statement Of Deviation Or Variation For The Quarter And Financial Year Ended On March 31 2026May 25, 2026
May 25, 2026Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2026May 25, 2026
May 25, 2026Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2026.May 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2026
May 19, 2026Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) Of The Company For The Quarter-IV And Financial Year Ended On March 31 2026May 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2026
May 14, 2026Intimation Under Regulation 30Apr 11, 2026
Apr 11, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2026
Apr 09, 2026Investor Roadshow Scheduled To Be Held On April 10 2026.Apr 07, 2026
Apr 07, 2026Announcement under Regulation 30 (LODR)-Credit RatingApr 02, 2026
Apr 02, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (Listing ObligatiMar 18, 2026
Mar 18, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 11, 2026
Feb 11, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 43.91
ATR(14)
Less Volatile 44.11
STOCH(9,6)
Oversold 18.20
STOCH RSI(14)
Neutral 26.28
MACD(12,26)
Bearish -6.43
ADX(14)
Weak Trend 14.92
UO(9)
Bearish 45.91
ROC(12)
Downtrend And Accelerating -3.36
WillR(14)
Oversold -83.08
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
